REVB News and Press, Revelation Biosciences Inc.

2024-07-19 17:05:14 ET More on Revelation Biosciences Seeking Alpha’s Quant Rating on Revelation Biosciences Historical earnings data for Revelation Biosciences Financial information for Revelation Biosciences Read the full article on Seeking Alpha ...

2024-06-25 06:18:00 ET 3 Ways That the 2024 Election Can Impact Penny Stocks Elections can significantly influence financial markets, including the domain of penny stocks . Penny stocks, often traded below five dollars per share, present a unique opportunity for investors aiming for...

A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...

-Top-line data forthcoming- Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced ...

2024-05-10 16:58:19 ET More on Revelation Biosciences Revelation Biosciences GAAP EPS of -$8.33 Seeking Alpha’s Quant Rating on Revelation Biosciences Historical earnings data for Revelation Biosciences Financial information for Revelation Biosciences ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, ...

2024-03-22 16:20:06 ET More on Revelation Biosciences Revelation Biosciences to raise ~$6.2M through public offering of shares Seeking Alpha’s Quant Rating on Revelation Biosciences Historical earnings data for Revelation Biosciences Financial informat...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended...

2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

– Prophylactic administration of Gemini (Intravenous PHAD®) reduces tissue damage and improves kidney function in a rat model of bilateral ischemic reperfusion induced acute kidney injury (AKI) - Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or ...